// App-Quantinova.ai

OA0041 : Prevalence of fungal‐sensitization and response to mepolizumab in patients with severe eosinophilic asthma

Researchers

Presenter

  • Kwon N

Principal Investigators

  • Howarth P

  • Israel E

  • Taill C

  • Quirce S

  • Mallett S

  • Bates S

  • Albers F

  • Wardlaw A

Medical Centers

  • GSK, Brentford, United Kingdom

  • Harvard Medical School & Asthma Research Center, Brigham & Women’s Hospital, Boston, MA, United States,

  • Hôpital Bichat, AP‐HP and INSERM U1152, Université Paris Diderot, Labex Inflamex, Paris, France

  • Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), and CIBERES, Instituto Carlos III, Madrid, Spain,

  • GSK, Uxbridge, United Kingdom

  • GSK, Stevenage, United Kingdom

  • US EPA, Research Triangle Park, NC, United States,

  • University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

  • United States

  • France

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Recepteur d'Origine Nantais

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01691521

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved